Stifel Nicolaus analyst David Grossman maintained a Buy rating on TriNet Group (TNET – Research Report) today and set a price target of $97.00.

Stifel Nicolaus analyst Jim Duffy maintained a Hold rating on Yeti Holdings (YETI – Research Report) today and set a price target of $40.00.

On Friday, Stifel analysts revised the price target for Hub Group (NASDAQ:HUBG) shares, lowering it slightly to $52 from the previous $53, while continuing to support the stock with a Buy rating.

Stifel Financial (NYSE:SF – Get Free Report) had its price target upped by equities researchers at UBS Group from $116.00 to $120.00 in a report issued on Monday,Benzinga reports. The brokerage ...

Stifel analyst W. Andrew Carter lowered the firm’s price target on Latham Group (SWIM) to $8 from $8.80 and keeps a Buy rating on the shares. The firm is updating its 2025 pool category ...

Stifel analysts reiterated their Buy rating on Lululemon Athletica Inc. (NASDAQ:LULU) with a maintained price target of $438, as the stock currently trades at $373.13. The firm's positive outlook ...

Stifel analysts revised the price target for Hub Group (NASDAQ:HUBG) shares, lowering it slightly to $52 from the previous $53, while continuing to support the stock with a Buy rating. Currently ...

Read Our Latest Stock Report on NFI NFI Group Trading Down 2.0 % Shares of NFI Group stock opened at C$13.25 on Wednesday. The company has a debt-to-equity ratio of 164.92, a quick ratio of 0.55 ...

Good day and welcome to the Stifel Financial fourth quarter financial ... year to 2025 and we were not expecting our institutional group to return to normalized productivity levels.

Kimco Realty Corp. Dep. Pfd. (Rep. 1/1000th 5.25% Cum. Redeem. Pfd. Series M)-0.84% Kimco Realty Corp. Dep. Pfd. (Rep. 1/1000th Pfd. Cl L)-0.48% Federal Realty Investment Trust Dep. Pfd. (Rep. 1 ...

Stifel Financial Corp. provides securities brokerage ... It operates through the following segments: Global Wealth Management, Institutional Group, and Other. The Global Wealth Management segment ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...